MARKET

PTCT

PTCT

PTC Therapeutics
NASDAQ

Real-time Quotes | Nasdaq Last Sale

57.98
+0.91
+1.59%
Opening 13:10 07/09 EDT
OPEN
57.63
PREV CLOSE
57.07
HIGH
57.98
LOW
56.50
VOLUME
420.87K
TURNOVER
--
52 WEEK HIGH
59.89
52 WEEK LOW
30.79
MARKET CAP
3.69B
P/E (TTM)
-11.9097
1D
5D
1M
3M
1Y
5Y

Analyst Rating

Based on 11 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target

The average PTCT stock price target is 59.90 with a high estimate of 85.00 and a low estimate of 48.00.

EPS

PTCT News

More
PTC therapeutics launches early-stage study of PTC857
Seeking Alpha - Article · 1d ago
PTC Therapeutics launches study of Parkinson's candidate
Seeking Alpha - Article · 1d ago
PTC Therapeutics Announces First Patient Dosed in Phase 1 Trial for PTC857
PR Newswire · 1d ago
PTC Therapeutics Announces First Patient Dosed In Phase 1 Trial For PTC857
Benzinga · 1d ago
Edited Transcript of PTCT.OQ earnings conference call or presentation 30-Apr-20 8:30pm GMT
Thomson Reuters StreetEvents · 06/29 19:04
European advisory group backs labeling change for PTC Therapeutics' Translarna
Seeking Alpha - Article · 06/29 15:18
PTC Therapeutics Announces CHMP Recommendation of Translarna (ataluren) Label Update for Non-Ambulatory Patients with Duchenne Muscular Dystrophy
PR Newswire · 06/29 13:00
PTC Therapies Announces a Positive Label Update for its Translarna
PTC Therapeutics, Inc. (NASDAQ:PTCT) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has recommended by a majority of votes to remove the statement
Benzinga · 06/29 12:05

Industry

Biotechnology & Medical Research
-0.34%
Pharmaceuticals & Medical Research
-0.81%

Hot Stocks

Symbol
Price
%Change

About PTCT

PTC Therapeutics, Inc. is a science-driven global biopharmaceutical company. The Company focused on the discovery, development and commercialization of clinically-differentiated medicines that provide benefits to patients with rare disorders. The Company have a portfolio pipeline that includes commercial products as well as product candidates in various stages of development, including clinical, pre-clinical and research and discovery stages, focused on the development of new treatments for multiple therapeutic areas, including rare diseases and oncology. The Company have two products, Translarna (ataluren) and Emflaza (deflazacort), for the treatment of Duchenne muscular dystrophy (DMD). The Company have a pipeline of gene therapy product candidates for rare monogenic diseases that affect the central nervous system (CNS), including PTC-AADC for the treatment of Aromatic L-Amino Acid Decarboxylase (AADC) and CNSA-001 for phenylketonuria (PKU) diseases.
More

Webull offers kinds of PTC Therapeutics, Inc. stock information, including NASDAQ:PTCT real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, PTCT stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading PTCT stock methods without spending real money on the virtual paper trading platform.